Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alpha Tau Medical Ltd ( (DRTS) ) has shared an update.
On December 9, 2025, Alpha Tau Medical Ltd. announced the successful treatment of the first patient in its U.S. trial for recurrent glioblastoma using its Alpha DaRT technology at The Ohio State University. This pilot study is part of Alpha Tau’s strategy to address high unmet needs in cancer treatment, supported by FDA’s Breakthrough Device Designation, and marks a significant milestone in neuro-oncology by offering a novel therapeutic approach for a highly resistant cancer.
The most recent analyst rating on (DRTS) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Alpha Tau Medical Ltd stock, see the DRTS Stock Forecast page.
Spark’s Take on DRTS Stock
According to Spark, TipRanks’ AI Analyst, DRTS is a Underperform.
Alpha Tau Medical Ltd is struggling with significant financial challenges, primarily due to a lack of revenue and ongoing cash burn. While technical indicators show a neutral trend, the valuation metrics reflect the company’s unprofitability. The absence of earnings call insights and corporate events limits additional context. Overall, the stock is risky with a low score of 38, suggesting caution for potential investors.
To see Spark’s full report on DRTS stock, click here.
More about Alpha Tau Medical Ltd
Founded in 2016, Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company focused on the research, development, and potential commercialization of Alpha DaRT, an innovative alpha-radiation cancer therapy designed for the treatment of solid tumors.
Average Trading Volume: 62,528
Technical Sentiment Signal: Buy
Current Market Cap: $329.5M
See more data about DRTS stock on TipRanks’ Stock Analysis page.